Skip to main content

Table 3 Summary of clinical findings (n = 50)

From: Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa

Clinical Findings Baseline Mid-cycle One month post-treatment p-value (Test for trend)*
Hearing lossa
 Bilateral 11 (22) 16 (32) 18 (36) 0.13
 Left ear only 4 (8) 3 (6) 1 (2) 0.17
 Right ear only 1 (2) 1 (2) 2 (4) 0.56
Type of hearing loss
 Sensorineural 15 (30) 19 (38) 19 (38)
 Conductive 0 0 0
 Mixed 1 (2) 1 (2) 1 (2)
Ototoxic hearing lossb 0 49 (98)  1 (2)   
 Bilateral     
 Left ear only     
 Right ear only     
  1. *Cochran-Armitage test for a linear trend in proportions
  2. aThe presence of a hearing loss was determined using the Silman and Silverman’s (1991) magnitude of hearing impairment. If thresholds exceeded 25 dB at more than three frequencies in the conventional frequency range, it was classified as a hearing loss
  3. bOtotoxic hearing loss was determined using the ASHA (1994) guidelines, which indicates the following: (a) ≥ 20 dB decrease at any one test frequency, (b) ≥10 dB decrease at any two adjacent frequencies, or (c) loss of response at three consecutive frequencies where responses were previously obtained